| Launch date | 14 Sep 2023 |
| Allotment date | 04 Oct 2023 |
| End date | 28 Sep 2023 |
| NAV | ₹10.00 |
Expense ratio, exit load and tax
Expense ratio: 0.92%
Inclusive of GST
Exit load
Exit load of 1%, if redeemed within 30 days.
Stamp duty
0.005% (from July 1st, 2020)
Tax implication
If you redeem within one year, returns are taxed at 20%. If you redeem after one year, returns exceeding Rs 1.25 lakh in a financial year are taxed at 12.5%.
Minimum investment amounts
| Min. for 1st investment | ₹100 |
| Min. for 2nd investment onwards | ₹100 |
| Min. for SIP | ₹100 |
Fund management
Dhruv MuchhalSep 2023 - PresentView details
Nikhil MathurSep 2023 - PresentView details
Fund house & investment objective
| Rank (total assets) | #2 in India |
|---|---|
| Total AUM | ₹7,57,067.19Cr |
| Date of Incorporation | 10 Dec 1999 |
|---|
HDFC Pharma And Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by HDFC Mutual Fund. This scheme was made available to investors on 10 Dec 1999. Nikhil Mathur is the Current Fund Manager of HDFC Pharma And Healthcare Fund Direct Growth fund. The fund currently has an Asset Under Management(AUM) of ₹7,57,067 Cr and the Latest NAV as of 19 Dec 2024 is ₹16.91. The HDFC Pharma And Healthcare Fund Direct Growth is rated Very High risk. Minimum SIP Investment is set to ₹100. Minimum Lumpsum Investment is ₹100. Exit load of 1%, if redeemed within 30 days. ;
Investment Objective
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. ;
| Fund benchmark | BSE Healthcare Index |
|---|